

## WATCHLIST

R

## **DISEASE BURDEN**

In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450 000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

## 

## **CLINICAL RELEVANCE**


圕

Delpazolid is a next-generation oxazolidinone antibiotic administered through oral and intravenous routes for the treatment of gram-positive bacterial infections including multidrug-resistant tuberculosis infections and pulmonary tuberculosis. Safety and efficacy data are still not mature.

SERVICE DELIVERY ENABLERS

assess manufacturing complexity.

Delpazolid is being developed as part of an oral TB treatment with bedaquiline, delamanid, and moxifloxacin, some of which are not widely accessible.



æ

This medicine is still in the R&D pipeline and therefore little is known about its potential positioning, pricing, and overall access plans.

